Recent progress in tuberculosis prophylactic vaccine strategies and some thoughts

VernacularTitle:结核病预防用新型疫苗策略的研究进展与思考
Author: Yue LU ¹ ; Shuai ZHOU ; Ying ZHANG ; Hongxia NIU
Author Information

1. 浙江中医药大学基础医学院，杭州　310053
Keywords: Tuberculosis; Mycobacterium tuberculosis; New vaccine strategies; Antigen; Adjuvant
From: Chinese Journal of Microbiology and Immunology 2023;43(5):406-412
CountryChina
Language:Chinese
Abstract: Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis. At present, the situation of tuberculosis control in China and even the world is severe. Bacillus Calmette-Guerin (BCG) vaccine is the only approved vaccine for tuberculosis, but its protective effect is limited. Hence, it is imperative to develop more effective tuberculosis vaccines. Currently, many new tuberculosis vaccine candidates are in clinical or preclinical trials. In this paper, to provide reference for the development of tuberculosis vaccines in China, the status of the research on vaccine candidates were reviewed and the progress in new tuberculosis vaccine strategies were summarized.